Our results underscore the importance of differentiating PC epigenome studies by histological subtype to enhance the efficacy of therapeutics targeting epigenetic regulators such as HDACs, KDMs, EZH2, ADAR1, or ZBP1. This evidence concerns the gene ADAR and pachyonychia congenita.